Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution

Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution Employers Need Now

Gene therapy is changing the way we think about healthcare and treatments for chronic diseases—and for self‑funded employers, it’s bringing serious financial shock potential. With many therapies priced between $2 million and $4 million per treatment, a single claim can throw an entire plan year off balance [1–4]. Additionally, as the number of FDA‑approved cellular and gene therapies keeps climbing, traditional stop‑loss coverage isn’t built to handle this level of volatility anymore [5, 6].

That’s why Planned Administrators, Inc. (PAI)—in partnership with SBR and the Association for CGT Solutions—created a purpose‑built Gene Therapy Stop‑Loss Solution. It’s designed to take the guesswork (and sticker shock) out of million‑dollar claims by helping employers:

• Avoid catastrophic financial surprises [7]
• Stabilize renewals year over year [8]
• Gain real predictability in a rapidly changing market [9]

In short, it’s the protection self‑funded employers need as gene therapy becomes more common—and far more expensive [5].

Gene Therapy Outcomes: High‑Impact, High‑Risk

Gene therapies are delivering life‑changing outcomes for conditions that once had no real treatment options, but the price tags are just as dramatic [5].

Industry forecasts suggest U.S. gene therapy spend could reach ~$18.5B by 2033 [10, 11]. As more therapies make it through the FDA pipeline, employer exposure grows—often without the historical claims data on which underwriters rely [5, 6].

That creates a tough reality for self-funded health plans:

• Claims are  infrequent, but financially overwhelming [12]
• Timing is unpredictable [8]
• A single event can disrupt renewals for years [8]

In other words, gene therapy brings incredible clinical value, but also unprecedented — and unpredictable — financial risk[ 5].

The Real Cost of Gene Therapy: What Employers Are Actually Facing

For self‑funded employers, the true cost of gene therapy goes far beyond the drug’s list price. While these treatments offer incredible clinical benefits, they also come with high‑cost claims that can overwhelm traditional stop‑loss coverage, and total exposure often rises when facility fees, conditioning/administration, and care coordination are included [13].

Real‑world price points (therapy list/WAC):

• Zolgensma® (SMA): ~$2.1–$2.3M for the therapy [1, 14].
• Skysona® (CALD): ~$3.0M for the therapy [2, 15].
• Hemgenix® (Hemophilia B): up to ~$3.5M for the therapy [3, 16].
• Casgevy® (SCD/β‑thal): ~$2.2M for the therapy [4, 17].

Note on administration/ancillary costs: Exact amounts vary by site of care, protocol, and patient factors; plans should expect additional six‑figure costs in many cases. [13].

Bottom line: gene therapy claims can exceed traditional stop‑loss thresholds quickly, reshaping a plan’s financial trajectory and impacting renewal pricing [8, 6].

Why Traditional Stop‑Loss Is No Longer Enough

Stop‑loss insurance is still a critical safety net for self‑funded employers—but the rise of gene therapy and other ultra‑high‑cost claims has exposed serious gaps in traditional models [8].

Here’s what today’s market data makes clear:

1. Gene therapy costs are outpacing historical models

High‑cost claims are now blowing past deductibles, because most of these therapies are new, there’s no historical data to guide accurate underwriting. Carriers are being forced to price forward, building assumptions into renewals that may or may not match actual risk [6].

2. Million‑dollar claims are no longer rare

Specialty medications, orphan drugs, and FDA‑approved gene therapies are all driving a sustained rise in $1 million+ claims [12].

3. Renewal volatility is hitting employers hard

After a catastrophic claim—or even the potential for one—stop‑loss premiums can spike dramatically. This makes budgeting unpredictable, especially for mid‑sized and self‑funded employers trying to maintain plan stability [8].

What’s needed now: a gene‑therapy‑ stop‑loss solution built specifically to handle the speed, scale, and financial impact of million‑dollar CGT claims [7, 18].

**A Smarter Gene Therapy Stop‑Loss Strategy:

PAI + SBR’s CGT Solution**

The Comprehensive Gene Therapy (CGT) Solution from PAI and SBR is built specifically to manage the financial exposure tied to gene therapy claims—one of the fastest‑growing and most unpredictable cost categories for self‑funded employers.

2026 Program Cost: $4.05 PEPM (eligibility, underwriting, and program terms apply) [20].
This fixed PEPM rate provides straightforward, predictable protection against multimillion‑dollar CGT claims, helping stabilize budgets and reduce renewal volatility [7].

How the CGT First‑Dollar Stop‑Loss Model Works

The CGT Solution uses a first‑dollar coverage structure, which means protection kicks in from the start of a covered gene therapy claim [7].

Here’s how the process works:

Step 1: The plan incorporates a pre-treatment provision into their plan document with contact information for a designated CGT Program Manager.

When a covered gene therapy is anticipated the rendering provider contacts the CGT Program manager and a pre-treatment review is completed.

Step2: The CGT Program Manager responds

Coordination of care through a Center of Excellence (COE) provider designated by the CGT Program Manager.

Step 3: The ACGT Reinsurance Program reimburses

The ACGT Reinsurance Program steps in and reimburses:

Beyond Reimbursement: Integrated Clinical & Administrative Support

When a candidate for gene therapy case is identified—whether covered or not—PAI and SBR provide hands‑on support to brokers, employers, and members:

• Coordination with credentialed Centers of Excellence
• Therapy and administration review
• Help with eligibility, adjudication, and early engagement
• Efforts to reduce cost impact for the plan and the member
• Access to patient navigation experienced in rare/complex conditions

If the reinsurance program covers the therapy, early identification of candidates, review and oversight must begin immediately, helping streamline the process, prevent delays, and avoid downstream disruption for the employer and member [13].

Integration With Captives and Reinsurance Structures

For employers using captive insurance or reinsurance, the CGT Solution fits smoothly into layered risk models. This flexibility becomes especially important when gene therapy claims can exceed $2.5 million [8]. Distributing risk across multiple layers, employers can reduce financial shock, protect captive performance, and maintain long‑term plan stability [6].

Why Employers Must Act Before Renewal Season

FDA‑approved gene therapies are increasing every year and stop‑loss underwriting is shifting just as quickly. Carriers are now pricing ahead of utilization, renewals are becoming harder to predict, and employers without CGT-specific protection face growing exposure [21, 6]

Proactively adopting gene therapy reinsurance coverage helps employers:

• Prevent renewal shock [8]
• Reduce laser risk [18]
• Protect employee access to high‑value therapies [11]
• Stabilize long‑term plan costs [8]

Waiting for the first claim is no longer a workable approach [8], early adoptionon a pre-service basis for a potential candidate is the only way to stay ahead of rapidly rising gene therapy risk.

Final Takeaway

Gene therapy is changing the landscape of catastrophic claims. But with PAI’s administrative expertise, SBR’s CGT Solution, and support from the Association for CGT Solutions, employers finally have a gene‑therapy‑specific stop‑loss strategy built for today’s cost and risk realities [19, 22].

You don’t have to absorb the impact. You can prevent it.

Ready to Protect Your Plan?

→ Learn More About the Gene Therapy Stop‑Loss Solution
→ Connect With PAI

Footnotes

1. Drugs.com. “Why is Zolgensma so expensive?” (Last updated Sept 4, 2024). Link
2. Ambiom. “The 4 most expensive single-dose drugs in 2022” (Nov 13, 2022) — Skysona priced at ~$3.0M. Link
3. Drugs.com. “Why is Hemgenix so expensive? … priced at $3.5M per dose.” (Last updated Nov 17, 2025). Link
4. BioPharma Dive. “Casgevy … will cost $2.2 million.” (Dec 8, 2023). Link
5. U.S. FDA. “Approved Cellular and Gene Therapy Products” (live list). Link
6. Lockton. “Medical stop loss – PS Market Update 2025 Q3.” (2025). Link
7. Amwins. “Gene Therapy Solutions” — first‑dollar protection and integration with stop‑loss. Link
8. QBE. “2025 Accident & Health Market Report” — renewal volatility & $1M+ claims dynamics. Link
9. Oliver Wyman/Guy Carpenter. “Stop‑Loss Market Update” summary—data/AI and portfolio pressure. (2025). Link
10. BioSpace/NovaOne press note. “U.S. gene therapy market … to hit USD 18.50B by 2033.” (Feb 26, 2025). Link
11. Nova One Advisor (reported by BioSpace), “U.S. Gene Therapy Market Size, Share & Growth Report, 2033” (Apr. 12, 2024). Link
12. Sun Life. “2025 High‑Cost Claims and Injectable Drug Trends Report.” (2024/2025). Link
13. Mercer. “Employers’ top four questions about cell and gene therapies” — admin/procedural components & navigation. (Aug 13, 2025). Link
14. Summit Re. “Gene Therapy Summary 2019–2024” — Zolgensma WAC noted ~$2.322M. (Feb 27, 2025). Link
15. Pharmacy Times. “Clinical Overview: Skysona …” (Nov 10, 2022). Link
16. MDLinx. “$3.5 million blood‑clotting shot … Hemgenix.” (Dec 13, 2022). Link
17. AAFP Blog. “Will the High Price of Gene Therapy for SCD Put This Cure out of Reach?” (Dec 12, 2023). Link
18. CVS Health / Aetna. “Providing financial protection from the impact of high‑cost gene therapies” (Gene Therapy Stop‑Loss Executive Summary). (2024). Link
19. PAI – “Cell and Gene Therapy (CGT)” program/insights page. Link
20. BCS Financial. “Now Quoting Gene Therapy Stop Loss for 2026.” (Sept 9, 2025). (PEPM example for market context). Link
21. PharmaBoardroom. “FDA Cell & Gene Therapy Approvals 2024.” (May 8, 2025). Link
22. Association for CGT Solutions (ACGTS) — organization site & program overview. Link